New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2012
12:12 EDTTYC, AMLN, RDS.A, ALIM, PNR, BNNY, XOM, SNX, BMY, CVXOn The Fly: Mid-Day Wrap
Stocks on Wall Street are lower at mid-day, after a report on durable goods orders in February fell short of expectations. After a meandering start to the session the averages have found their direction and it is lower. Each of the major equity indices is firmly in negative territory and at session lows. The market began the session mixed and seemed unaffected by the generally in-line durable goods orders report. The market also ignored the weekly DOE energy inventory reports until the averages broke out of their tight range and moved to the downside, gaining negative momentum as the day progresses... ECONOMIC EVENTS: In the U.S., durable goods orders for February rose 2.2%, versus expectations for a 3.0% increase. The core reading, which excludes transportation items, increased 1.6%, versus the expected increase of 1.7%... MARKET NEWS: Exxon Mobil (XOM), Shell (RDS.A), BP (BP), and Chevron (CVX) all declined as oil prices dropped following statements from France's energy minister about a possible joint oil reserve release coordinated between France, the U.S. and the U.K... Organic pasta maker Annie's (BNNY) soared after the company's initial public offering, which priced above its expected range at $19. The stock is up almost 72% to $32.63 near noon... MAJOR MOVERS: Among the notable gainers were Amylin (AMLN), after Bloomberg reported that the company rejected a $22 per share takeover offer from Bristol-Myers (BMY) earlier this year, and Pentair (PNR), after the company agreed to merge with Tyco's (TYC) Flow Control business to create a combined company that sees pro forma 2012 revenues of $7.7B. Noteworthy losers included SYNNEX (SNX), following a downgrade at Citigroup on the company's disappointing guidance for Q2, and Alimera (ALIM), after the company said last night that based on recent discussions with European regulatory authorities it thinks it will take longer than originally anticipated to obtain marketing authorizations for it ILUVIEN drug... INDICES: Near noon, the Dow was down 83.97, or 0.64%, to 13,113.76; the Nasdaq was down 24.20, or 0.78%, to 3,096.15; and the S&P 500 was down 11.26, or 0.80%, to 1,401.26.
News For A;CVX;BNNY;AMLN;BMY;PNR;TYC;SNX;ALIM From The Last 14 Days
Check below for free stories on A;CVX;BNNY;AMLN;BMY;PNR;TYC;SNX;ALIM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 21, 2014
07:21 EDTBMYFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 19, 2014
11:12 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 17, 2014
09:55 EDTTYC, TYCTyco initiated with an Outperform at CLSA (pre-open)
Target $48.
April 16, 2014
18:38 EDTCVXFidelity Contrafund adds to Tesla position, Reuters says
Subscribe for More Information
April 15, 2014
08:23 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTBMYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
08:15 EDTBMYBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
07:06 EDTALIMAlimera Sciences receives new PDUFA date for ILUVIEN
Subscribe for More Information
April 10, 2014
16:00 EDTAOptions Update; April 10, 2014
Subscribe for More Information
12:46 EDTCVXChevron management to meet with Jefferies
Meetings to be held in London on April 16-17 hosted by Jefferies.
09:37 EDTCVXActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:02 EDTCVXChevron, YPF continue development of Vaca Muerta Shale in Argentina
Subscribe for More Information
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Subscribe for More Information
April 9, 2014
17:02 EDTCVXChevron says Q1 earnings expected to be lower than Q4
Subscribe for More Information
17:00 EDTCVXChevron says Q1 earnings expected to be lower than Q4
Subscribe for More Information
11:43 EDTBMYGilead defended by analysts after recent pullback
Subscribe for More Information
10:06 EDTCVXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:23 EDTBMYEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
06:11 EDTBNNYPoint72 raises passive stake in Annie's to 6.1% from 5.2%
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use